Improving clinical outcomes of chronic hepatitis B virus infection
Journal
Expert review of Gastroenterology and Hepatology
Journal Volume
9
Journal Issue
2
Pages
141-154
Date Issued
2015
Author(s)
Abstract
Chronic hepatitis B virus (HBV) infection is a global health problem, leading to cirrhosis, hepatocellular carcinoma (HCC) and liver-related deaths. Universal hepatitis B vaccination is the most cost-effective way to eradicate HBV infection with the remarkable reduction of chronic carriage, neonatal fulminant hepatitis and childhood HCC. The introduction of highly effective antiviral agents, including lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fumarate and pegylated interferons further improve short-, medium- and long-term outcomes of chronic HBV infection, such as ALT normalization, HBV DNA suppression, HBeAg seroconversion, HBsAg seroclearance, fibrosis regression, reduction of cirrhosis, HCC, liver-related deaths and the need for liver transplantation. Above all, sustained and profound viral suppression is the key to improve the clinical outcomes of chronic hepatitis B. ? 2015 Informa UK, Ltd.
SDGs
Other Subjects
adefovir dipivoxil; alanine aminotransferase; besifovir; emtricitabine; entecavir; hepatitis B vaccine; hepatitis B(e) antigen; immunomodulating agent; lamivudine; nucleoside analog; peginterferon alpha2b; telbivudine; tenofovir alafenamide; tenofovir disoproxil; virus DNA; alanine aminotransferase; antivirus agent; hepatitis B(e) antigen; chronic liver failure; death; drug efficacy; hepatitis B; history; human; liver cell carcinoma; liver cirrhosis; liver fibrosis; liver transplantation; outcome assessment; remission; Review; seroconversion; vaccination; blood; disease management; Hepatitis B, Chronic; treatment outcome; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Treatment Outcome
Publisher
Expert reviews Ltd.
Type
review